XML 67 R57.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Segment Information - Reportable Segment Information (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Net sales:        
Net sales $ 2,889 $ 2,929 $ 5,788 $ 5,956
Segment Adjusted Operating EBITDA:        
Adjusted Operating EBITDA 588 510 1,166 1,013
Depreciation & Amortization 246 287 524 563
Interest expense (79) (101) (162) (201)
Other (expense) income, net (15) 11 (16) 8
Restructuring and other charges, net (2) (7) (5) (59)
Goodwill, impairment loss (64) 0 (64) 0
(Gains) Losses on business disposals (368) 5 (368) 19
Loss on held for sale classification (282) 0 (282) 0
Acquisition, divestiture, and integration related costs 59 45 117 76
Strategic initiative costs (12) (9) (16) (22)
Regulatory costs (19) (14) (54) (19)
Other gains (losses) 5 (3) 4 2
Income before taxes 183 50 298 64
Integration-related costs (3) (20) (5) (30)
Transaction related costs   (5)   (5)
Business divestiture costs 56 20 112 41
Nourish        
Segment Adjusted Operating EBITDA:        
Restructuring and other charges, net (1) (2) (3) (32)
Health & Biosciences        
Segment Adjusted Operating EBITDA:        
Restructuring and other charges, net 0 (1) (1) (11)
Scent        
Segment Adjusted Operating EBITDA:        
Restructuring and other charges, net (1) (4) (1) (14)
Pharma Solutions        
Segment Adjusted Operating EBITDA:        
Restructuring and other charges, net 0 0 0 (2)
Operating Segments | Nourish        
Net sales:        
Net sales 1,478 1,564 2,974 3,217
Segment Adjusted Operating EBITDA:        
Segment Adjusted Operating EBITDA 232 181 448 389
Operating Segments | Health & Biosciences        
Net sales:        
Net sales 558 522 1,089 1,035
Segment Adjusted Operating EBITDA:        
Segment Adjusted Operating EBITDA 165 145 324 276
Operating Segments | Scent        
Net sales:        
Net sales 603 592 1,248 1,200
Segment Adjusted Operating EBITDA:        
Segment Adjusted Operating EBITDA 137 117 294 222
Operating Segments | Pharma Solutions        
Net sales:        
Net sales 250 251 477 504
Segment Adjusted Operating EBITDA:        
Segment Adjusted Operating EBITDA $ 54 $ 67 $ 100 $ 126